Adenocarcinoma [sub-distribution hazard ratio (SHR) 2.40, 95% confidence interval (CI) 1.11–5.19,P = 0.027], poor performance status (SHR 1.91, 95% CI 1.18–3.09, P = 0.008), and EGFR wild-type (SHR 1.81, 95% CI 1.07–3.07, P = 0.028) were associated with an increased risk of VTE. Here, EGFR is linked to adenocarcinoma.